about
Hepatitis C: a review for primary care physiciansHepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activityIdentification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virusMutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.Amantadine therapy for chronic hepatitis CManaging Occupational Risks for Hepatitis C Transmission in the Health Care SettingMonitoring Response to Antiviral Therapy for Patients with Chronic Hepatitis C Virus Infection by a Core-Antigen AssayReplicative Homeostasis III: implications for antiviral therapy and mechanisms of response and non-responseNon-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral GenomesBinding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase InhibitorsCell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted VariantCytopathic and Noncytopathic Interferon Responses in Cells Expressing Hepatitis C Virus Subgenomic RepliconsSelection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase InhibitorsHepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutationHepatitis C virus replicons: dinosaurs still in business?Hepatitis C Virus entry: the early steps in the viral replication cycleHepatitis C: a clinical reviewThe Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in ChinaHepatitis C treatment: where are we now?Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C.Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.Phlebotomy improves histology in chronic hepatitis C males with mild iron overload.Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.PCBP2 enhances the antiviral activity of IFN-α against HCV by stabilizing the mRNA of STAT1 and STAT2.Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients.Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked to apolipoprotein A-I.A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses.Cell penetrable humanized-VH/V(H)H that inhibit RNA dependent RNA polymerase (NS5B) of HCV.The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0.Envelope 2 protein phosphorylation sites S75 & 277 of hepatitis C virus genotype 1a and interferon resistance: a sequence alignment approach.Protein kinase expression as a predictive factor for interferon response in chronic hepatitis C patientsInhibition of full length hepatitis C virus particles of 1a genotype through small interference RNAInhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.Collaboration between Hepatologists and Primary Care Physicians in Treating Patients with Chronic Hepatitis C.Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infectionSocial support and clinical outcomes during antiviral therapy for chronic hepatitis C
P2860
Q22306040-A8047A98-AE58-4873-AF57-7C04CE6FC55BQ24300867-61B630A3-7EDF-4AC8-8957-9868D1EB2168Q24658111-EDAAA7E5-FF95-4A2F-A5C0-7D647DAE99DBQ27472610-F53C442A-D1BD-490D-B451-FAC0D91B8015Q27472717-FB390CD4-C41B-4E8B-A342-1E1435B920FBQ27473307-1F506A2F-5B3A-4B65-B214-1E28F78F9872Q27477626-0025BBBB-4116-457E-A09F-AE1AA135940AQ27478083-34C54783-1046-4404-A49B-BD3498C59177Q27478215-9B1C800A-AB17-4FE6-9222-EC0836599610Q27478313-2B865837-C23D-4EBD-9743-C1F156CDE4F1Q27480348-324D274A-DC3C-464D-8979-4C1F64242243Q27480926-AA236E14-07A8-4B43-8594-E2ABBB04D39CQ27485033-7F51D149-4FC1-4BC1-9434-AF1186F93F32Q27485424-BD6D9996-1F3D-4218-9D8C-27D5D7E363B7Q27486249-7774F255-CB70-415C-BA4E-A4E82D55466AQ27486836-14F526CA-A4B2-4E7D-8F09-ABD5047733E9Q27488905-7B28ACC8-E402-4023-BC4B-94A182EF18D7Q27489242-A3311A54-0348-481B-8221-346CC78F0C9EQ27490788-BFF8CEA1-1640-4897-8331-E5B98BE2EC79Q28550281-1D3E9A4D-2EFD-41AD-8C23-50D720B04A4AQ30378509-E436455D-565E-4BEC-9FE3-84EE5214D902Q30767073-C63CD410-A8CB-43F2-8FE5-F0436336EB06Q33373813-361660B0-242A-4A8F-A56A-5C139F722738Q33374135-9357C441-C977-4EF3-A781-8E1E2877A132Q33629438-4B71DD2A-E749-4B77-9290-A56A9F2D6E78Q33866448-ABF58521-43D5-42CF-8E47-89E3F6215E5CQ34055577-B2032988-844A-4F59-9320-53FD9EFA46D5Q34103218-1E66888F-0B98-461B-A6B5-409AC7EE65C9Q34359523-531D2548-60B3-4750-A394-830E04109CFAQ34427768-29458D83-D63C-4008-B157-30CB582EF054Q34474314-BD92D349-2513-410A-B56D-FDA964FDB828Q34588247-28D473C1-D2B1-4074-980F-883380CF348CQ34605687-5B1C3FE3-2AE9-43AB-9607-0F59291089ABQ34615960-50609CF7-8914-41C8-AF87-8CDA85AB923BQ34961241-3AE0EAF7-9D89-4583-9898-793C0D533816Q34980601-FE58AA93-7C9A-4115-A278-450B33FABB3FQ35004972-9A1F57AE-8CD1-44D6-BAE1-E81A32B658D2Q35022767-4C96B89A-F773-4C5A-B2D0-1C6A84DB21E6Q35136312-5CD6DA22-E7C1-4443-B3D8-B7729A8B475FQ35393471-3B38B7F7-FB41-4F6C-9E2B-D997FC6CF3C6
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Optimal therapy of hepatitis C.
@ast
Optimal therapy of hepatitis C.
@en
Optimal therapy of hepatitis C.
@nl
type
label
Optimal therapy of hepatitis C.
@ast
Optimal therapy of hepatitis C.
@en
Optimal therapy of hepatitis C.
@nl
prefLabel
Optimal therapy of hepatitis C.
@ast
Optimal therapy of hepatitis C.
@en
Optimal therapy of hepatitis C.
@nl
P2860
P356
P1433
P1476
Optimal therapy of hepatitis C.
@en
P2093
Jay H Hoofnagle
P2860
P304
P356
10.1053/JHEP.2002.36228
P407
P433
P577
2002-11-01T00:00:00Z